It was reported that a patient underwent a left side atrial tachycardia cardiac ablation procedure and the patient experienced pericardial effusion treated with surgical intervention and hospitalization.The physician heard a steam pop during the ablation phase.An effusion in the heart was then noticed.Additional information was received on 14-mar-2024 which increases the severity level of the pericardial effusion to a condition requiring surgical intervention.As such, this event is now considered mdr reportable with an awareness date of 14-mar-2024.It was reported that transseptal puncture and ablation performed.The patient underwent surgery in another hospital.Patient stayed hospitalized 7 days, until the (b)(6) 2024.Ablation was performed before the effusion was noticed.Correct settings were selected on devices.
|
(b)(6).The device has been reported as discarded, therefore no product investigation can be performed, and the customer complaint cannot be confirmed.A manufacturing record evaluation was performed for the finished device number lot 31228838l and no internal action related to the complaint was found during the review.If additional information is received regarding this event, a supplemental 3500a report will be submitted to the fda.This report is being submitted pursuant to the provisions of 21 cfr, part 803.This report may be based on information which has not been investigated or verified prior to the required reporting date.This report does not reflect a conclusion by biosense webster, inc., or its employees that the report constitutes an admission that the product, biosense webster, inc., or its employees caused or contributed to the potential event described in this report.If information is obtained that was not available for the initial report, a follow-up report will be filed as appropriate.Manufacturer's reference number: (b)(4).
|